SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Strides Shasun trades with traction on the bourses

13 Sep 2017 Evaluate

Strides Shasun is currently trading at Rs. 967.20, up by 19.25 points or 2.03% from its previous closing of Rs. 947.95 on the BSE.

The scrip opened at Rs. 952.00 and has touched a high and low of Rs. 972.35 and Rs. 946.00 respectively. So far 21304 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 1259.00 on 03-Feb-2017 and a 52 week low of Rs. 848.50 on 24-May-2017.

Last one week high and low of the scrip stood at Rs. 990.40 and Rs. 913.00 respectively. The current market cap of the company is Rs. 8648.16 crore.

The promoters holding in the company stood at 31.12%, while institutions and non-institutions held 49.40% and 19.47% respectively.

Strides Shasun has received approval from the United States Food & Drug Administration (USFDA) for Potassium Citrate Extended-Release Tablets USP, 5 mEq, 10 mEq, and 15 mEq. According to IMS data, the US market for Potassium Citrate is approximately $110 million.

The company will be the second generic player to commercialize the product. The product, which is the first approval for an Extended Release tablet for the company, will be launched immediately.

Potassium Citrate, a urinary alkalinizing agent, is used for preventing certain types of kidney stones. It works by neutralizing some of the acid in the urine, which helps reduce the formation of crystals.

Strides Shasun (formerly known as Strides Arcolab) is engaged in manufacturing, sale and export of pharmaceutical products. It offers general tablets, hard gelatin and soft gelatin capsules, sachets, potent drugs and semi-solids.

Strides Pharma Scien Share Price

1070.90 69.10 (6.90%)
23-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1679.85
Dr. Reddys Lab 1333.05
Cipla 1305.85
Zydus Lifesciences 947.10
Lupin 2340.20
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×